shutterstock_2163578799_halawi

Halawi / Shutterstock.com

23 March 2023Big PharmaLiz Hockley

US refuses to compel lower prices for Pfizer and Astellas cancer drug

NIH rejects petition to use “march-in” rights to allow cheaper competition | Xtandi is “widely available” to public, federal agency says.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

NIH chooses not to use ‘march-in rights’ in prostate drug row

21 June 2016 The US National Institutes of Health has decided not to exercise its “march in-rights” for the Xtandi prostate drug, which is marketed by Astellas Pharma, despite calls from politicians to license the drug in a bid to lower its price.

Actavis hit with IP suit over prostate cancer drug

6 December 2016 Astellas Pharma, Medivation and the regents of the University of California have collectively sued Actavis for alleged patent infringement over Xtandi, a treatment for prostate cancer.

More on this story

NIH chooses not to use ‘march-in rights’ in prostate drug row

21 June 2016 The US National Institutes of Health has decided not to exercise its “march in-rights” for the Xtandi prostate drug, which is marketed by Astellas Pharma, despite calls from politicians to license the drug in a bid to lower its price.

Actavis hit with IP suit over prostate cancer drug

6 December 2016 Astellas Pharma, Medivation and the regents of the University of California have collectively sued Actavis for alleged patent infringement over Xtandi, a treatment for prostate cancer.

More on this story

NIH chooses not to use ‘march-in rights’ in prostate drug row

21 June 2016 The US National Institutes of Health has decided not to exercise its “march in-rights” for the Xtandi prostate drug, which is marketed by Astellas Pharma, despite calls from politicians to license the drug in a bid to lower its price.

Actavis hit with IP suit over prostate cancer drug

6 December 2016 Astellas Pharma, Medivation and the regents of the University of California have collectively sued Actavis for alleged patent infringement over Xtandi, a treatment for prostate cancer.

More features

LSPN Europe: Navigating the EPO and lessons from the UPC’s frontline

Paul Hastings reinforces London office with high-tech patent litigator

Gene tech firm fends off injunction in test kit dispute

Comparing life sciences IP in Brazil and the US

Gilead awarded $30m over counterfeit HIV drug scheme

EPO invalidates human milk patent after Nestle opposition

Bayer gains exclusive licence for heart drug in Japan

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings